$ADTX News

ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish?

Aditxt (ADTX) Stock Sinks 20% After-Hours: Here’s What’s Going On

Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On?

Aditxt (ADTX) Stock Surges Nearly 17% After Hours: Here's Why

Aditxt and Ignite announce merger plans with strategic partner

What's Going On With Aditxt Stock Wednesday?

Why Is ADTX Stock In Spotlight Today?

Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million

Aditxt Unit Ignite Proteomics To Merge With A Strategic Counterparty At An Implied Equity Valuation Of ~$150M

Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection

Aditxt Unit Ignite Proteonomics Launches Prospective Oncology Registry, Enrolling Up To 10K Patients To Pair It CLIA-Certified Reverse Phase Protein Array Platform With Structured Clinical Outcomes

Aditxt, Inc. Appoints Jeffrey M. Busch as Interim Chief Executive Officer; Founder and Former CEO of $1B NYSE Enterprise Which Delivered ~8.5% Dividends to Shareholders

Aditxt Appoints Jeffrey M. Busch Interom CEO, Effective May 31

Aditxt Q1 EPS $(790.49) Up From $(198.07 thousand) YoY, Sales $12.159K Up From $1.018K YoY

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-27 Reverse Stock Split Effective at the Open of Trading on May 18, 2026

Aditxt shares are trading lower. Its subsidiary Ignite Proteonomics was included in a study published in the journal npj Precision Oncology.

Aditxt shares are trading lower. Its subsidiary Ignite Proteonomics was included in a study published in the journal npj Precision Oncology.

Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients

Aditxt's Ignite Proteomics Was Featured In NPJ Precision Oncology

Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer